Reprint Disclaimers Should Include Mention Of Failed Studies, Lawyers Advise
Executive Summary
Companies disseminating journal reprints on off-label drug uses should include information on failed studies or attach a complete bibliography, Pfizer Senior Assistant General Counsel George Evans told a Food & Drug Law Institute conference Nov. 18.